Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Galidesivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galidesivir SCHEMBL30477706 | 1.00 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL4838048 | 1.00 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL15525360 | 1.00 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL25424734 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL15717852 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL16884051 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL23102311 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL17760735 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL12468816 | 0.99 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL15718263 | 0.99 | PNP (1.00) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867351-B | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-04-23 | — | — | CN | claimed |
| CN-114867351-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2022-08-05 | — | — | CN | claimed |
| CN-120037399-A | Programmable polymeric drugs | 索尼集团公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119896726-A | Alkaline phosphatase preparation and use thereof | 特里瓦生物制剂有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-118477090-A | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-118359622-A | Preparation method of Li Siwei intermediate | 上海陶术生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-114867351-B | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-04-23 | — | — | CN | disclosed |
| CN-113667011-B | Method for preparing antigen binding units | 北京大学 | 2024-03-29 | — | — | CN | disclosed |
| EP-3160475-B1 | SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS | JANSSEN PHARMACEUTICALS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-116670161-A | Methods of preventing or treating viral-induced organ injury or failure using IL-22 dimers | 亿一生物医药开发(上海)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116421608-A | Application of ganalyvir in-vitro inhibition/elimination of rabies virus | 中国疾病预防控制中心病毒病预防控制所 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023126968-A1 | A PROCESS FOR THE SYNTHESIS OF BCX-1777 AND BCX-4430 | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2023-07-06 | — | — | WO | disclosed |
| CN-116390725-A | Hydroxy pioglitazone for treating pulmonary inflammation and interstitial lung disease | 米尼奥尔克斯治疗有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-116018143-A | Compositions comprising diltiazem for the treatment of viral infections caused by SARS-COV-2 virus | 里昂第一大学 | 2023-04-25 | — | — | CN | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11590155-B2 | Substituted nucleosides, nucleotides and analogs thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-114867351-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | PNP 48/4885MTAP 56/4885 |
| US-11590155-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | PNP 1/4885MTAP 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.